GERARDO RIVERA: Open Payments
NPI 1992399125 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 10 payments from 8 companies in 2025. Trend: 2023 $2,027 · 2024 $1,213 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 2 | $254 |
| ViiV Healthcare Company | 2 | $235 |
| Gilead Sciences, Inc. | 1 | $122 |
| AstraZeneca Pharmaceuticals LP | 1 | $74 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
| Janssen Biotech, Inc. | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
| Exelixis Inc. | 1 | $21 |
Products named: REZDIFFRA, APRETUDE, Yeztugo, FLUMIST QUADRIVALENT, ADSTILADRIN, ERLEADA, COSENTYX, CABOMETYX.
Industry payments across TX — which companies pay providers there.
